Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 17 of 17 for “"Sirolimus"”.
-
Developing polypyrrole coated coronary stents for extended release of Sirolimus
… with distinct chemical/physical properties. Sirolimus is a hydrophobic anti-proliferative drug which retains in the vessel wall to inhibit SMC proliferation. During this investigation polypyrole coated devices were created with the ability to release sirolimus over a therapeutically relevant …
-
Durch Sirolimus induzierte frühe Veränderungen des Proteoms und Phosphoproteoms in humanen T-Lymphoblasten
… Proteoms und Phosphoproteoms während einer durch Sirolimus (SRL) induzierten Inhibition der Lymphozytenproliferation zu untersuchen. Materialien und Methoden: Die Proliferationstests wurden mit humanen CCRF-CEM T-Lymphoblasten unter verschiedenen SRL-Konzentrationen durchgeführt. Das Gesamtprotein …
-
Ανίχνευση όψιμου κατάγματος ενδοστεφανιαίας πρόθεσης σε ασυμπτωματικούς ασθενείς μετά την εμφύτευση επικαλυμμένων με sirolimus ενδοστεφανιαίων προθέσεων και μη επικαλυμμένων ενδοστεφανιαίων προθέσεων με ψηφιακή ακτινοσκόπηση
Το κάταγμα ενδοστεφανιαίας προθέσης (stent fracture, SF) αποτελεί μια αρκετά σπανία επιπλοκή μετά την αγγειοπλαστική και συνδιάζεται ουσιαστικά με την χρήση των επικαλλυμένων με σιρόλιμους stents (SES). Ο ρόλος της ακτινοσκόπησης με την FPDD στην εντόπιση των SF δεν έχει μελετηθεί επαρκώς. Μέθοδος …
-
Untersuchung costimulatorischer Signalwege bei chronischer Transplantatabstoßung und Langzeit-Organakzeptanz nach allogener Nierentransplantation an einem experimentellen Hirntod-Spender-Transplantationsmodell
… dass eine Kombination aus niedrig dosiertem Sirolimus und CsA einen synergistischen immunsuppressiven Effekt nach Nierentransplantation aufweisen. rPSGL-Ig wirkt additiv und reduziert frühe unspezifische oder auch Alloantigen-unabhängige hervorgerufene Schädigung gegenüber dem Transplantat.
-
Interventionelle Behandlung intrakranieller Gefäßstenosen mittels ballongestützter Angioplastie und Implantation unbeschichteter und medikamentenbeschichteter Stentsysteme
… 32 stent implantations (26 uncoated stents and 6 sirolimus-coated stents). The medium degree of post-interventional stenoses was 11.39% (stent 4.68% and balloon-supported angioplasty 30.9%). There were new diffusion disorders after 16.3% of the interventions, major strokes in 3 cases (6.97%) and …
-
Application Of In Vivo Flow Profiling To Stented Human Coronary Arteri
… separately with bare metal stents (BMS) and Sirolimus Eluting Stents (SES). The stent assignments were blinded until the end of the study. The study was repeated for the patients after 9 months. The predicted WSS ranged from (0.1- 8 N/m2) and was categorized into five classes: low ( < 1 …
-
Pharmacokinetic and pharmacodynamic studies of mycophenolic acid in renal transplant recipients
… patients who were on mycophenolate mofetil/sirolimus/steroids, for conventional study (n=6) and for the PK-PD modeling (n=46), were included.The mean total Cmax and AUC were 11.99B17.22 mg/L and 46.81B121.44 mg.h/L respectively. The free fraction of MPA was ranged from 0.4-1.06%. The mean …
-
Clinical outcome and Predictive factors of Coronary aneurysm after Percutaneous Coronary Intervention
… PCI with longer DES implantation, especially Sirolimus eluting stent. Poor clinical outcomes including in-stent restenosis and targel lesion revascularization were increased in the patients with CAA/PSS than without CAA/PSS but there was no difference of cardiovascular and all-cause mortality. …
-
Divergent Roles of PI3K and Akt in Rapamycin-induced Cardioprotection against Ischemia-Reperfusion Injury
… ischemia-induced cellular injury. Rapamycin(sirolimus) inhibits protein synthesis through inhibition of the mammalian target ofrapamycin (mTOR). This property of rapamycin has led to its current clinical applications in drug-eluting stents and in immunosuppresive treatment to organ transplant …
-
Análisis obsevacional para evaluar la eficacia y seguridad de los mTORi en la esfera oncológica en el paciente trasplantado hepático
… The appearance of mTOR inhibitors (mTORi, sirolimus, everolimus) within the immunosuppressive arsenal as non-nephrotoxic agents may represent an advance in the tumor control of these patients, since they are basically used in the area of oncology as antiproliferative agents. Objectives: 1): …
-
Association of Protein Phosphatase 2A with S6 Kinase Is Regulated In an MTOR-Dependent Manner
The mammalian target of rapamycin (mTOR) pathway senses nutrient and growth factors to regulate protein synthesis and cell growth. Strict control of the components of this pathway is essential for cells to reach an appropriate size. Aberrant mTOR signaling has been implicated in multiple diseases …
-
Der ELISA-basierte Nachweis von C4d nach Lebertransplantation - ein hilfreicher Marker zur Differentialdiagnose zwischen akuter Abstoßung und rezidivierender Hepatitis-C-Infektion?
… doses of calcineurin-inhibitors. MMF and sirolimus are also state of the art in treatment of rejection reactions. However, acute rejection accounts for the majority of complications (20-40%) in the process of liver transplantation. Hepatitis-C-induced liver cirrhosis is one of the most …
-
The Development of Methods to Account for Physiologic Dynamic Changes and Their Effects on the Pharmacokinetics of Therapeutic Monoclonal Antibodies and other Therapeutics
… also received either methotrexate or tacrolimus/sirolimus immune suppression. Methotrexate significantly lowered the incidence of anti-variable region antibodies at moderate mAb dose (P<0.05), while tacrolimus/sirolimus did likewise at moderate and high doses (P<0.01) of mAb. With the exception …
-
Έλεγχος του βαθμού ενδοθηλιοποίησης των στεφανιαίων αρτηριών με τη μέθοδο της οπτικής συνεκτικής τομογραφίας σε ασθενείς με ενδοστεφανιαίες προθέσεις που εκλύουν πακλιταξέλη έξι μήνες μετά την αρχική τους εμφύτευση στα πλαίσια οξέος στεφανιαίου συνδρόμου
… την εμφύτευση επικαλυμμένων stents που εκλύουν sirolimus, τα αντίστοιχα δεδομένα που αφορούν στο βαθμό νεοενδοθηλιακής κάλυψης και ατελούς εναπόθεσης των επικαλυμμένων stents που εκλύουν πακλιταξέλη είναι, πριν τη δημοσίευση της παρούσας εργασίας, περιορισμένα. Αυτό ισχύει ιδιαιτέρως για …
-
Mathematical modeling and simulation of intravascular drug delivery from drug-eluting stents with biodegradable PLGA coating
… and aqueous phases. The model predicted in vitro sirolimus release from PLGA stent coating, and demonstrated the significance of the developed model by comparing with existing drug transport models. An integrated model for intravascular drug delivery from a PLGA-coated DES is developed in the last …
-
Gene Therapy and Stem Cell Therapy to Improve the Outcome of Human Islet Transplantation
… and is dosed with two immunosuppressive drugs, sirolimus and tacrolimus and a monoclonal antibody drug daclizumab to prevent the graft rejection. However, despite the administration of immunosuppressive drugs and the recent improvement in islet isolation, preparation and transplantation, insulin …
-
Studies of immunoglobulin receptors and human proximal tubular cells
… GM-CSF released by PTEC. Cyclosporine, FK506 and sirolimus were shown to inhibit both the production of FN and the growth of PTEC at high doses, thereby exerting an antiproliferative effect. Both simvastatin and fluvastatin inhibited LPS induced production of IL-6, IL-8 and GM-CSF, FN and …